68Ga-PSMA11 PET应答对接受紫杉类化疗的前列腺癌患者的预后价值
本研究纳入103例接受紫杉类化疗的转移性前列腺癌患者(转移性激素敏感型57例、去势抵抗型46例),评估传统生化与影像应答标准及68Ga-PSMA11 PET适配或特异性系统对总生存的预后价值。结果显示任一标准判定的进展均与死亡风险至少升高2.5倍相关,aPERCIST判定的进展风险最高(HR 11.4),PSMA PET进展标准简单易用且预后效用最佳。
要点
- 任一应答标准判定的进展均与死亡风险至少升高2.5倍相关,aPERCIST的进展对完全/部分缓解HR为11.4。
- PSMA PET进展标准简单易用,识别了大多数进展患者,对总生存的预后效用最佳。
- aPERCIST判定的部分/完全缓解患者死亡风险更低、总生存更长,优于进展或稳定患者。
核心结论
- PSMA PET应答标准(PSMA PET进展、aPERCIST、适配前列腺癌工作组标准3)在接受紫杉类化疗的转移性前列腺癌男性中具有高预后效用。
- PSMA PET进展标准简单易用,识别了大多数进展患者,对总生存的预后效用最佳。
- aPERCIST判定的部分/完全缓解识别出应答者亚组,其结局优于进展或稳定患者。
- 未来研究有必要修正当前仅区分进展与非进展的范式,并通过影像标准识别真正的治疗应答者。
研究设计与样本
- 共纳入103例接受紫杉类化疗的患者,其中转移性激素敏感型前列腺癌57例、去势抵抗型前列腺癌46例。
- 所有患者至少接受2次前列腺特异性膜抗原(PSMA)PET扫描(基线和治疗后最多3个月内)。
- PSMA PET应答通过RECIST 1.1、适配前列腺癌工作组标准3(用PSMA PET替代骨扫描)、aPERCIST和PSMA PET进展标准进行评估。
- 生化应答由前列腺特异性抗原下降至少50%确定。
- 按去势状态进行亚组分析,采用单变量Cox比例风险回归(含Harrell一致性指数)和Kaplan-Meier检验(含对数秩统计)分析。
主要发现
- 26例(25%)患者经RECIST 1.1评估为不可测量病灶。
- 单变量回归中,任一应答标准判定的进展均与死亡风险至少升高2.5倍相关,aPERCIST判定的进展对完全/部分缓解的风险比最高(HR 11.4)。
- 按去势状态分层后观察到相似模式。
- 任一标准判定的进展在总体和亚组分析中均与总生存显著缩短相关。
- aPERCIST判定的部分/完全缓解患者较进展或稳定患者死亡风险更低、总生存更长。
关键数值与推荐
- 生化应答定义为前列腺特异性抗原下降至少50%。
- aPERCIST分层为进展、稳定和部分/完全缓解。
- 其他标准分层为进展或非进展。
- 任一标准判定的进展与死亡风险至少升高2.5倍相关。
- aPERCIST判定的进展对完全/部分缓解的风险比为11.4。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出未来研究有必要修正当前仅区分进展与非进展的范式,并通过影像标准识别真正的治疗应答者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study was performed to assess the prognostic utility of conventional biochemical and imaging response criteria and 68Ga-PSMA11 PET-adapted or -specific systems regarding overall survival (OS) in men with metastatic hormone-sensitive and castration-resistant prostate cancer (PC) treated with taxane-based chemotherapy. Methods: A total of 103 patients (metastatic hormone-sensitive PC, n = 57; castration-resistant PC, n = 46) underwent taxane-based chemotherapy. All patients had a minimum of 2 prostate-specific membrane antigen (PSMA) PET scans (at baseline and up to 3 mo after treatment). PSMA PET response was assessed by RECIST 1.1, adapted Prostate Cancer Working Group Criteria 3 (using PSMA PET instead of bone scan), aPERCIST, and PSMA PET progression (PPP) criteria. Response by each criterion was stratified by either progressive disease (PD) or non-PD. For aPERCIST, stratification by PD, stable disease (SD), and partial/complete remission (PR/CR) was performed. Biochemical response was determined by a prostate-specific antigen decrease of at least 50%. Subgroup analyses were performed by castration status. Univariable Cox proportional hazards regression analyses including Harrell's concordance indices were calculated to investigate the association of PD by response criteria and OS. Kaplan-Meier tests including log-rank statistics were calculated for survival analyses. Results: Twenty-six (25%) patients had unmeasurable disease by RECIST 1.1. PD by any response criterion was associated with an at least 2.5-fold increased risk of death and was highest for PD versus CR/PR by aPERCIST (hazard ratio, 11.4) on univariable regression. Stratified by castration status, a similar pattern was observed. PD by any criterion as associated with significantly shortened OS across overall and subgroup analyses. PR/CR by aPERCIST identified patients with lower risk of death and longer OS compared with patients with PD or SD. Conclusion: PSMA PET-based response criteria (PPP, aPERCIST, adapted Prostate Cancer Working Group Criteria 3) have high prognostic utility in men with metastatic PC undergoing taxane-based chemotherapy. PPP is simple to use, identified most patients with PD, and showed best prognostic utility regarding OS. PR/CR by aPERCIST identifies a subgroup of responders (PR/CR) showing better outcomes than patients with PD or SD. Future studies are warranted to amend the current paradigm relying on mere differentiation of PD versus non-PD in metastatic PC and to identify true treatment responders by imaging criteria.
引用
- Lunger L, Chantadisai M, Karimzadeh A, et al. Prognostic Role of 68Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy. J Nucl Med. 2022. PMID: 36581373. doi:10.2967/jnumed.122.264962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。